MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers, Election of Directors, Appointment of Principal Officers.
On March 15, 2019, the Board of Directors (the “Board”) of MEDITE Cancer Diagnostics, Inc. (the “Company”) terminated the Employment Agreement (the “Agreement) of its Chief Financial Officer, Gary Pickett, effective immediately. Mr. Pickett agreed to the termination and to waive any further rights under the Agreement, except for the payment of deferred and accrued salary and documented expenses.
About MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT)
MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The Company offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The Company offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The Company also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers.
